Back to Journals » Neuropsychiatric Disease and Treatment » Volume 14

Response to the paper titled "Identification of a novel CACNA1A mutation in a Chinese family with autosomal recessive progressive myoclonic epilepsy"

Authors Graves TD

Received 12 July 2018

Accepted for publication 16 July 2018

Published 11 September 2018 Volume 2018:14 Pages 2329—2330

DOI https://doi.org/10.2147/NDT.S179068

Checked for plagiarism Yes

Editor who approved publication: Dr Roger Pinder


Tracey D Graves

Department of Neurology, North West Anglia NHS Foundation Trust, Hinchingbrooke Hospital, Huntingdon, UK

I have just read this article.1 I have issues with the authors denoting the insertion of CAG as a new mutation. This is located within a polyglutamine tract, which is known to be polymorphic in this gene. The normal number of CAG repeats in exon 47 of the CACNA1A gene ranges from 4 to 18; over 21 CAG repeats lead to the neurological condition SCA6.2 Indeed, in this paper, Lv et al1 call the mutation insertion c.6975_6976insCAG, that is, the insertion of one CAG codon; however, on the sequencing figure, the two affected members of the pedigree have 14 CAG repeats, whereas the control and unaffected descendant have 11 repeats. So, if they were going to call this a mutation, it would be an insertion of three CAG repeats. They also seem somewhat confused about the nature of this mutation, as in a later figure they suggest that the insertion of glutamine also causes deletion of alanine, which is not backed up by the data given on their sequencing figure, showing an in-frame insertion of CAG, which would not delete the following alanine residue.1

View the original paper by Lv and colleagues.

Dear editor

I have just read this article.1 I have issues with the authors denoting the insertion of CAG as a new mutation. This is located within a polyglutamine tract, which is known to be polymorphic in this gene. The normal number of CAG repeats in exon 47 of the CACNA1A gene ranges from 4 to 18; over 21 CAG repeats lead to the neurological condition SCA6.2 Indeed, in this paper, Lv et al1 call the mutation insertion c.6975_6976insCAG, that is, the insertion of one CAG codon; however, on the sequencing figure, the two affected members of the pedigree have 14 CAG repeats, whereas the control and unaffected descendant have 11 repeats. So, if they were going to call this a mutation, it would be an insertion of three CAG repeats. They also seem somewhat confused about the nature of this mutation, as in a later figure they suggest that the insertion of glutamine also causes deletion of alanine, which is not backed up by the data given on their sequencing figure, showing an in-frame insertion of CAG, which would not delete the following alanine residue.1

This is a known polymorphism and, therefore, cannot be attributed to be the cause of disease in these patients.

Disclosure

The author reports no conflicts of interest in this communication.


References

1.

Lv Y, Wang Z, Liu C, Cui L. Identification of a novel CACNA1A mutation in a Chinese family with autosomal recessive progressive myoclonic epilepsy. Neuropsychiatr Dis Treat. 2017;19(13):2631–2636.

2.

Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet. 1997;15(1):62–69.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Neuropsychiatric Disease and Treatment ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Neuropsychiatric Disease and Treatment editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]